McAvoy David R.
Known title: EVP, Chief Legal OfficerCIK: 0001758842
McAvoy David R.'s purchase track record
McAvoy David R. has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/5/2025 | TEVA | $21K | +50.2% | +63.8% | +4.0% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
this person other insiders at TEVA
Transaction History
| TEVA | ▲ Buy | Open Market | 1,113 | $21K | 9/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 1,677 | $27K | 3/5/2025 | View on chart |
| TEVA | ▼ Sell | Open Market | 3,150 | $50K | 3/4/2025 | View on chart |
| TEVA | ▲ Buy | Option Exercise | 16,741 | — | 3/4/2025 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Teva Receives FDA Approval for Weltruza, Announces R&D Day
Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.
Teva Receives FDA Approval for Weltruza, Announces R&D Day. Teva Pharmaceutical Industries secured FDA approval for Weltruza, a once‑monthly long‑acting injectable for schizophrenia. The approval follows the company’s announcement of an R&D day in New York City, where it will discuss its pipeline and future research plans. Barclays raised its price target to $47, citing the new product launch and potential growth in the schizophrenia market. These developments add fresh catalysts to Teva’s outlook.